Maravai Lifesciences Holdings Inc (MRVI)

Maravai Lifesciences Holdings, Inc. is a San Diego-based life sciences company founded in 2014 and listed on NASDAQ under the ticker MRVI. The company develops products that support drug therapy, vaccine, cell and gene therapy, and diagnostic development across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin and Central America. Its operations are organized into two segments: TRILINK and CYGNUS. TRILINK focuses on products used in gene therapy, nucleoside chemistry, oligonucleotide therapy, molecular diagnostics, and related research, including reagents for DNA and RNA synthesis, modification, labeling, and purification, along with messenger RNA, oligonucleotides, CleanCap-based building blocks, custom enzyme development, and protein labeling and detection products. CYGNUS provides analytical products and custom services for biologic manufacturing development, including antibody and assay development, ELISA kits, ancillary reagents, viral clearance prediction kits, and impurity and contaminant testing tools.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-MRVI
$5.18
-30.6% Downside
Overvalued
$7.42
-0.6% Downside
Fair
Fair
0.0%
November 5, 2026
9.1x
8.9x
1.905 B
1.367 B
9.6%
76.7%
4.9
46.3%
Valuation • Fair Value

Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) Fair Value by Valuation Model

Review the available estimates for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.18

Estimated downside of 30.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.14

Discounted cash flow valuation reference.

Comps Fair Value

$6.04

Comparable-company valuation reference.

Analyst Price Target

$7.42

Analysts imply downside of 0.6%.

How to read these valuation models

Use the 5 available valuation references for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

208.8 M

Current operating scale indicator.

Revenue Forecast

212 M

Forward revenue estimate.

EBITDA

-19.745 M

Current operating profitability reference.

EBITDA Forecast

33.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.70

No elevated caution signal from this screen.

Altman Z-Score

4.9

Relatively strong balance-sheet zone.

FCF / Net Income

46.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

44

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) Stock Forecast & Technical Outlook

Review Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) has a Buy consensus, with 5 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 4
Sell 0
FAQ Fast Investor Answers

Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) Stock FAQ

Data-supported answers about Maravai Lifesciences Holdings Inc (NASDAQ-MRVI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.18
Estimated downside 30.6%
Valuation Rating
Overvalued
Estimated downside of 30.6%
Analyst Target
$7.42
Implied downside 0.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is $5.18. This implies an estimated downside of 30.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 30.6% versus the current market price.

The available analyst price target for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is $7.42. The analyst target implies estimated downside of 0.6%.

The current financial health read for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is November 5, 2026.

The latest available data indicates no current dividend yield for Maravai Lifesciences Holdings Inc (NASDAQ-MRVI).

The current market capitalization listed for Maravai Lifesciences Holdings Inc is 1.905 B.

The current enterprise value listed for Maravai Lifesciences Holdings Inc is 1.367 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Maravai Lifesciences Holdings Inc is NASDAQ-MRVI, and the stock is listed on NASDAQ.

Maravai Lifesciences Holdings Inc (NASDAQ-MRVI) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Maravai Lifesciences Holdings Inc is 9.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Maravai Lifesciences Holdings Inc is 76.7%. Free float helps investors understand how much of the share base is available for public trading.